ARTICLE | Product Development
The missing piece
How AbbVie's Boehringer deal advances its Humira replacement strategy
March 14, 2016 7:00 AM UTC
In preparation for biosimilar competition for Humira adalimumab, AbbVie Inc. is developing a portfolio of products intended to treat the blockbuster's many indications. Last week's deal with Boehringer Ingelheim GmbH added a large missing piece, giving AbbVie a late-stage product in psoriasis that could be the best-in-class anti-IL-23 agent and an advance over IL-17 mAbs.
Humira is approved to treat at least 11 indications across the U.S. and EU and accounted for worldwide net revenues of $14 billion in 2015 - 61% of AbbVie's net revenues that year...